Morningstar

Innovent Biologics Inc 01801

Stock XHKG Rating as of Sep 30, 2026

News

Eli Lilly, InnoCare Sign Deal That Could Top $3 Billion

Global News Select Sep 24, 2026, 5:09:00 AM
Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal Cancer in China

PR Newswire Aug 6, 2026, 12:00:00 AM
Innovent Biologics Shares Surge on Spero Deal That Could Be Worth $1.1 Billion

Global News Select Jul 15, 2026, 7:03:00 AM
Chinese Biopharma Stocks Rally as Investors Favor Healthcare Over AI

Global News Select Jun 29, 2026, 9:48:00 AM
Innovent Biologics Surges After Signing Up to $10.5 Billion Deal With Pfizer

Global News Select May 29, 2026, 5:44:00 AM
Pfizer, Innovent Sign Licensing Deal to Develop 12 Cancer Drugs

Global News Select May 28, 2026, 11:28:00 PM
Innovent Biologics Shares Surge After Swing to Profitability

Global News Select Mar 27, 2026, 9:57:00 AM
Innovent Biologics Surges After Striking Partnership Deal with Eli Lilly

Global News Select Feb 9, 2026, 6:00:00 AM
China's Innovent Strikes Cancer Drug Deal With Takeda for Up to $11.4 Billion — Update

Global News Select Oct 22, 2025, 10:37:00 AM
China's Innovent Strikes Cancer Drug Deal With Takeda for Up to $11.4 Billion

Global News Select Oct 22, 2025, 4:48:00 AM

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2026 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.